Cann Reaffirms “Average” Rating for Insys Therapeutics (INSY)
Cann reissued their average rating on shares of Insys Therapeutics (NASDAQ:INSY) in a research report released on Friday, The Fly reports.
Other equities research analysts also recently issued research reports about the company. ValuEngine downgraded Insys Therapeutics from a sell rating to a strong sell rating in a report on Thursday. Oppenheimer reissued a hold rating on shares of Insys Therapeutics in a report on Sunday, November 12th. Zacks Investment Research downgraded Insys Therapeutics from a hold rating to a sell rating in a report on Thursday, February 22nd. Finally, Jefferies Group cut their price objective on Insys Therapeutics from $14.00 to $11.00 and set a buy rating on the stock in a report on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. Insys Therapeutics has a consensus rating of Hold and an average price target of $9.38.
Shares of Insys Therapeutics (NASDAQ:INSY) opened at $7.77 on Friday. Insys Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.02.
TRADEMARK VIOLATION NOTICE: “Cann Reaffirms “Average” Rating for Insys Therapeutics (INSY)” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/cann-reaffirms-average-rating-for-insys-therapeutics-insy/1908675.html.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.